The continuous glucose monitor (CGM) began its clinical life as a lifeline for people with type 1 diabetes — a device that replaced the daily ritual of fingerstick testing with a subcutaneous sensor streaming glucose readings every five minutes to a smartphone. Today, CGM has evolved into something the medical community did not anticipate: a window into the metabolic health of everyone, diabetic or not.
How CGM Technology Works
Current-generation CGM sensors — including the Dexcom G7, Abbott Freestyle Libre 3, and Medtronic Simplera — consist of a filament-thin electrochemical sensor inserted just beneath the skin (typically on the upper arm or abdomen) that measures interstitial fluid glucose every 1–5 minutes. A transmitter wirelessly relays readings to a paired device, with alarms for hypo- and hyperglycemic thresholds. Sensor wear time ranges from 10 to 15 days depending on platform.
The newest generation, including Stelo (Dexcom's over-the-counter CGM approved in 2024), requires no prescription and is designed specifically for non-diabetic users interested in metabolic insight.
What's Normal — and What's Not
In a metabolically healthy individual, fasting glucose runs 70–99 mg/dL, and postprandial peaks — which occur 30–90 minutes after eating — should not exceed 140 mg/dL. CGM data from non-diabetic populations has revealed something surprising: a significant minority of individuals with "normal" fasting glucose and HbA1c spike repeatedly above 140 mg/dL after common foods, a phenomenon called impaired glucose tolerance (IGT) that standard annual bloodwork entirely misses.
A landmark study from Stanford (published in Cell, 2015) placed CGMs on 57 non-diabetic healthy adults and found extraordinary individual variation: the same food — white bread, for example — raised glucose by 18 mg/dL in one person and 108 mg/dL in another. The implication: population-wide dietary guidelines based on averaged glycemic index data are a poor guide to individual metabolic response.
Glucose Variability as a Health Biomarker
Beyond absolute glucose values, CGM introduces the concept of glucose variability — the amplitude and frequency of glucose fluctuations throughout the day. Emerging research links high glucose variability (measured as standard deviation or coefficient of variation) to:
- Increased oxidative stress and endothelial damage
- Higher cardiovascular event risk (independently of mean glucose)
- Cognitive impairment and mood instability
- Accelerated aging at the cellular level (telomere shortening)
- Impaired sleep architecture (nighttime glucose spikes correlate with REM disruption)
CGM in Athletic Performance Optimization
Elite athletes have adopted CGM to optimize fueling strategies with a precision previously unachievable. Endurance athletes can observe in real time when glycogen depletion begins, calibrate carbohydrate intake during training blocks, and identify which pre-competition meals maintain stable glucose during the critical hours before an event. Research from the University of Toronto found that CGM-guided fueling in cyclists reduced bonking (hypoglycemic fatigue) by 34% compared to standard fueling protocols.
Strength athletes are using CGM to optimize post-workout protein-carbohydrate timing — observing that the anabolic window correlates closely with the post-exercise glucose nadir, when insulin sensitivity peaks.
The Personalized Nutrition Revolution
Companies including Levels Health, Nutrisense, and January AI have built software platforms that combine CGM data with food logging, activity data, and sleep tracking to generate highly personalized dietary recommendations. Machine learning models trained on large CGM datasets can now predict glycemic response to foods with approximately 70% accuracy from gut microbiome profiles alone — suggesting a future where a single sequencing test might replace weeks of CGM monitoring for dietary optimization.
Emerging Medical Applications
Beyond wellness, CGM is finding new clinical applications:
- Pre-diabetes detection: CGM identifies IGT patterns years before HbA1c crosses diagnostic thresholds, enabling much earlier lifestyle intervention.
- Polycystic ovary syndrome (PCOS): Insulin resistance, a core feature of PCOS, is revealed with much greater sensitivity by CGM than fasting insulin measurements.
- Post-COVID metabolic syndrome: A significant subset of long COVID patients show acquired glucose dysregulation detected by CGM despite normal HbA1c.
- Critical care ICU monitoring: Continuous rather than intermittent glucose monitoring in ICU patients reduces hypoglycemic episodes associated with tight insulin protocols.
Limitations and Considerations
CGM interstitial glucose lags behind blood glucose by 5–15 minutes — relevant during rapid glucose changes but generally adequate for trending and pattern recognition. Sensor accuracy (measured as mean absolute relative difference, or MARD) has improved substantially: the Freestyle Libre 3 achieves MARD of 7.8%, approaching the accuracy threshold for insulin dosing decisions.
For most non-diabetic users, a 2–4-week wear period generates sufficient data for meaningful dietary and lifestyle adjustments. The technology is not a treatment — it is a measurement tool — but measurement, in metabolic health, often is the treatment: seeing a 160 mg/dL glucose spike after a "healthy" smoothie is one of the most powerful behavioral change tools available in preventive medicine. Healthcare facilities can find relevant diagnostic equipment in our catalog.
